About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
821
JPY
0
(0.00%)
Apr 16, 3:30 pm JST
5.76
USD
Apr 16, 2:30 am EDT
Result
PTS
outside of trading hours
823.9
Apr 16, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.99
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
830 JPY 5.79 USD
Previous Close Apr 15
821 JPY 5.74 USD
High Apr 16, 9:03 am
831 JPY 5.80 USD
Low Apr 16, 2:33 pm
813 JPY 5.71 USD
Volume
37,000
Trading Value
0.03B JPY 0.21M USD
VWAP
821.7 JPY 5.77 USD
Minimum Trading Value
82,100 JPY 576 USD
Market Cap
5.61B JPY 0.04B USD
Number of Trades
103
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
Slightly High
1-Year Average
603
1-Year High Jun 27, 2024
12,293
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 0 847,700
Apr 4, 2025 0 875,800
Mar 28, 2025 0 928,500
Mar 21, 2025 0 900,100
Mar 14, 2025 0 901,100
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.